Cycle threshold values at which a specific number of dogs out of 11 dogs was able to detect SARS-CoV-2 in samples from Merida, Yucatán, México. by Víctor M. Vidal-Martínez (18707335)

Subjects:

Results of a dog’s detections after exposure to sweat samples from positive and negative people to SARS-CoV-2, together with the Ct values of the RT-qPCR test of each person partic... by Víctor M. Vidal-Martínez (18707335)

Subjects:

Sensitivity and specificity of 11 dogs trained to detect SARS -CoV-2 from the sweat of positive and negative people from Mérida, Yucatán compared with the reference test (RT-qPCR).... by Víctor M. Vidal-Martínez (18707335)

Subjects:

Details of the 11 fully trained dogs exposed to sweat samples of SARS-CoV-2 positive and negative humans. by Víctor M. Vidal-Martínez (18707335)

Subjects:

Effect of down-regulation and up-regulation of CRNN on cell apoptosis. by Changji Li (4806930)

Subjects:

IRE1 silencing downregulates cell cycle genes and engages TP53 and specific CDK inhibitors. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

RNA sequencing analyses of βA3ΔG91 lenses relative to WT lenses. by Akosua K. Boateng (21672931)

Subjects:

<i>Ctsz</i>^{<i>−/−</i>} mice have higher lung burden and earlier spleen dissemination during acute infection followed by greater chronic inflammation and mortality risk.... by Rachel K. Meade (22216529)

Subjects:

Endogenous IRE1 protein can localize to the nuclear envelope. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

Growth of certain cancer cell lines requires IRE1 but not its enzymatic activity. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

<i>Leptospira interrogans</i> from Okinawa induces epithelial barrier disruption with different kinetics. by Tetsuya Kakita (4922584)

Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects: